HCQ, a standard drug used for SLE [14] exhibited potent anti-inflammatory effects by inhibiting the release of pro-inflammatory cytokines, such as IL-17A, while concurrently promoting the release of anti-inflammatory cytokines, including IL-10 and TGF-β1. This evidence concerns the gene TGFB1 and systemic lupus erythematosus.